论文部分内容阅读
目的：探讨乳腺癌组织中微血管计数、ＣＤ４４Ｖ６表达与临床病理因素及预后的关系。方法：对经治疗后随访８年以上的乳腺癌病例，应用免疫组化法，分别检测癌组织中微血管计数及ＣＤ４４Ｖ６表达。将其结果与影响预后的临床病理因素及生存状况比较。结果：肿瘤内微血管数与组织学分级、临床分期、淋巴结转移呈正相关。死亡组癌组织内微血管数明显高于存活组。 ＣＤ４４Ｖ６在癌组织中的表达率为 ８０．４％，淋巴结阳性及组织学分级高的病例 ＣＤ４４Ｖ６阳性表达率增加，死亡组ＣＤ４４Ｖ６表达明显高于生存组。结论：微血管计数及ＣＤ４４Ｖ６可做为估计乳腺癌预后和指导临床治疗有价值的参考指标。
Objective: To investigate the relationship between microvessel count, CD44V6 expression and clinicopathological factors and prognosis in breast cancer. Methods: After treated for more than 8 years in breast cancer cases, immunohistochemical methods were used to detect the microvessel count and CD44V6 expression in cancer tissue. The results and the impact of prognosis of the clinical and pathological factors and survival status comparison. Results: The number of microvessel in the tumor was positively correlated with histological grade, clinical stage and lymph node metastasis. The number of microvessels in the death group was significantly higher than that in the surviving group. The positive rate of CD44V6 expression in cancer tissues was 80.4%. The positive rate of CD44V6 in lymph node positive and histological grade was higher. The expression of CD44V6 in death group was significantly higher than that in survival group. Conclusion: Microvessel count and CD44V6 can be used as a valuable reference for estimating prognosis and guiding clinical treatment of breast cancer.